Vaxart, Inc.: Form 10-Q for the period ended Sep 30, 2014
Filed with the SEC on Nov 7, 2014 and accepted by EDGAR at Nov 7, 2014, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-07-01 to 2014-09-30 | $700.0k | us-gaap:Revenues |
| Research and development | 3 months2014-07-01 to 2014-09-30 | $4.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-07-01 to 2014-09-30 | −$7.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2014-07-01 to 2014-09-30 | −$6.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-07-01 to 2014-09-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-07-01 to 2014-09-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-07-01 to 2014-09-30 | 35,029,300 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2014-07-01 to 2014-09-30 | −$11.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2014-09-30 | $57.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-09-30 | $76.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-09-30 | $97.3m | us-gaap:Assets |
| Current liabilities | At period end2014-09-30 | $19.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-09-30 | $19.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-09-30 | $77.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-14-020053. Last ingested by Listed: Nov 5, 2026, 18:48 ET. Listed shows no prices and gives no investment advice.